Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study
-
- Thomas Benfield
- Center of Research and Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark
-
- Jacob Bodilsen
- Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark
-
- Christian Brieghel
- Department of Infectious Diseases, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark
-
- Zitta Barrella Harboe
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Marie Helleberg
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
-
- Claire Holm
- Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
-
- Simone Bastrup Israelsen
- Center of Research and Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark
-
- Janne Jensen
- Department of Medicine, Kolding Hospital, Kolding, Denmark
-
- Tomas Østergaard Jensen
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
-
- Isik Somuncu Johansen
- Research Unit for Infectious Diseases, Odense University Hospital, University of Southern Denmark, Odense, Denmark
-
- Stine Johnsen
- Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
-
- Birgitte Lindegaard
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Jens Lundgren
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Christian Niels Meyer
- Department of Medicine, Zealand University Hospital, Roskilde, Denmark
-
- Rajesh Mohey
- Department of Medicine, Herning Hospital, Herning, Denmark
-
- Lars Pedersen
- Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
-
- Henrik Nielsen
- Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark
-
- Stig Lønberg Nielsen
- Research Unit for Infectious Diseases, Odense University Hospital, University of Southern Denmark, Odense, Denmark
-
- Niels Obel
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
-
- Lars Haukali Omland
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
-
- Daria Podlekareva
- Department of Respiratory Medicine, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
-
- Birgitte Klindt Poulsen
- Department of Clinical Pharmacology, Aalborg University Hospital, Aalborg, Denmark
-
- Pernille Ravn
- Department of Infectious Diseases, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark
-
- Haakon Sandholdt
- Center of Research and Disruption of Infectious Diseases, Department of Infectious Diseases, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark
-
- Jonathan Starling
- Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
-
- Merete Storgaard
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
-
- Christian Søborg
- Department of Infectious Diseases, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark
-
- Ole Schmeltz Søgaard
- Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
-
- Torben Tranborg
- Department of Medicine, Esbjerg Hospital, Esbjerg, Denmark
-
- Lothar Wiese
- Department of Medicine, Zealand University Hospital, Roskilde, Denmark
-
- Hanne Rolighed Christensen
- Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Description
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied. Death within 30 days and need of mechanical ventilation (MV) were compared by inverse probability of treatment weighted (ITPW) logistic regression analysis and shown as odds ratio (OR) with 95% confidence interval (CI).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The 30-days mortality rate of 1694 individuals treated with remdesivir and dexamethasone in addition to SOC was 12.6% compared to 19.7% for 1053 individuals receiving SOC alone. This corresponded to a weighted OR of 30-day mortality of 0.47 (95% CI: .38–.57) for patients treated with remdesivir and dexamethasone compared to patients receiving SOC alone. Similarly, progression to MV was reduced (OR 0.36; 95% CI: .29–.46).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Treatment of moderate to severe COVID-19 during June through December that included remdesivir and dexamethasone was associated with reduced 30-day mortality and need of MV compared to treatment in February through May.</jats:p> </jats:sec>
Journal
-
- Clinical Infectious Diseases
-
Clinical Infectious Diseases 73 (11), 2031-2036, 2021-06-10
Oxford University Press (OUP)
- Tweet
Details 詳細情報について
-
- CRID
- 1360017287057545088
-
- ISSN
- 15376591
- 10584838
-
- Data Source
-
- Crossref